• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC MEXICO ADMIRAL XTREME CATHETER, ANGIOPLASTY, PERIPHERAL, TRANSLUMINA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC MEXICO ADMIRAL XTREME CATHETER, ANGIOPLASTY, PERIPHERAL, TRANSLUMINA Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Diarrhea (1811); Hematoma (1884); Nausea (1970); Pain (1994); Vomiting (2144); Restenosis (4576)
Event Date 11/16/2021
Event Type  Injury  
Event Description
A journal article was submitted detailing a study to assess the feasibility and safety of hybrid angiography consisting of carbon di oxide (co2) angiography supplemented by small doses of iodinated contrast medium (icm) in the endovascular treatment of chronic limb threatening ischemia (clti) patients with pre-existing chronic kidney disease (ckd). 206 patients were included in the study. Medt ronic¿s trailblazer support catheter was used in combination with other guidewires for crossing lesions. After crossing the lesion, plain balloon angioplasty was completed using medtronic¿s 0. 035 admiral xtreme balloon and/or 0. 018 pacific plus balloon. Stenting was reserved for residual stenosis
=
30% or flow-limiting dissection. Hemostasis of the access site was done by manual compression. Technical success was defined as restoration of inline flow to the foot with <(><<)>30% residual stenosis. Perioperative morbidity and mortality, defined as complications and death occurring within 30 days following the procedure. Long-term outcomes measured included assisted primary patency, defined as patency maintained with the use of an additional surgical or endovascular procedures as long as occlusion of the primary treated site has not occurred; secondary patency, defined as patency obtained with the use of an additional procedures after occlusion occurs; clinically driven¿target lesion revascularization (cdtlr), defined as any re-intervention at the target lesion(s) due to symptoms or drop of abi of
=
20% or >. 15 when compared to post-procedure baseline abi; and amputation-free survival (afs), defined as time until a major (above-ankle) amputation of the index limb or death from any cause. Technical success was achieved in 95. 6% of cases. Technical failures occurred in nine patients due to either inability to cross the lesion (5 patients) or failed re-entry into the true lumen during subintimal recanalization (4 patients). All nine failures received subsequent bypass surgery that were successful in 8 patients and failed in one patient who underwent a later below-knee amputation. No deaths or major systemic complications (stroke or myocardial infarction) occurred within 30 days of the procedure. One patient received a major amputation after failed endovascular and a subsequent open surgical attempt for revascularization. None of the patients suffered from respiratory or neurological complications. Other noted complications included access site hematoma (10 patients), transient abdominal pain (6 patients, 2. 9%), nausea (5 patients), vomiting (2 patients), and diarrhoea (2 patients). Procedural outcomes for the population included major amputation (11. 7%), and death (6. 8%). Primary patency reported as 64. 5 +/- 3. 5% at 12 months. Freedom from cd-tlr reported as 74. 7 +/- 3. 1% at 12 months. Amputation free survival reported as 81 +/- 2. 8% at 12 months. There is no established or suspected causal relationship between the device(s) and the death events.
 
Manufacturer Narrative
Title: safety and efficacy of hybrid angiography in chronic lower extremity ischemia patients at risk of contrast-induced acute kidney injury author: ashraf g. Taha, mahmoud saleh, haitham ali journal: vascular and endovascular surgery year: 2022 vol/issue: 56 (2) ref: 10. 1177/15385744211055908. Average age, majority gender, date of publication journal reported death but there is no information to suggest the device caused or contributed to the death events. Deaths are common occurrences in clinical studies, however the cause(s) of death are often not characterized or clearly associated with a particular product. Therefore, deaths will not be considered reportable unless clearly stated as being associated with a medtronic device. If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameADMIRAL XTREME
Type of DeviceCATHETER, ANGIOPLASTY, PERIPHERAL, TRANSLUMINA
Manufacturer (Section D)
MEDTRONIC MEXICO
av. paseo del cucapah #10510
tijuana,bc 22570
MX 22570
Manufacturer (Section G)
MEDTRONIC MEXICO
av. paseo del cucapah #10510
tijuana,bc 22570
MX 22570
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key13892357
MDR Text Key293152460
Report Number9612164-2022-01160
Device Sequence Number1
Product Code LIT
Combination Product (y/n)N
Reporter Country CodeEG
PMA/PMN Number
K173515
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional,Company Representative
Reporter Occupation
Type of Report Initial
Report Date 03/24/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/24/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/15/2022
Was Device Evaluated by Manufacturer? No Answer Provided
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 03/24/2022 Patient Sequence Number: 1
-
-